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With the progress of genomics and targeted therapies, an
increasing number of cancer somatic mutations are
becoming clinically actionable: predictive of drug sensi-
tivity or resistance. However, clinical samples are often
suboptimal for their comprehensive detection. Indeed,
contamination with normal cells or the presence of
diverse subclones affects their detection by high-through-
put sequencing. Ultra-deep targeted sequencing (UDT-
Seq) is an assay combining microdroplet PCR amplifica-
tion of exonic sequences followed by a direct, oriented
sequencing at high depth of coverage, therefore allowing
the detection of low prevalence mutations [1]. Standard
sequencing analysis tools that were developed to analyze
whole genome and exome shotgun sequencing do not
take advantage of UDT-Seq’s specific design where each
sequencing read originates from a known strand and
location. We propose a complete analysis package (Muta-
Scope) dedicated to the analysis of UDT-Seq or similar
PCR-based high-throughput sequencing. After alignment
to the genome, MutaScope separates the sequencing
reads with respect to the amplicons and strand of origin.
This allows the experimental measurement of an error
rate along the amplicons, which is used to calculate a var-
iant likelihood and rank candidate mutations. Using a set
of reference samples, or matched normal DNA, Muta-
Scope then identifies germline and somatic variants and
reports them in a unified expanded variant call format.
The performance of MutaScope was evaluated on 676
amplicons using a set of calibration samples harboring
variants at defined prevalence down to 1%. Overall,
MutaScope’s sensitivity and positive predictive value
(PPV) were >96% and >75%, respectively; which is higher
than the standard variant calling strategies (approxi-
mately 70% and 70%, respectively). MutaScope detects
more than 73% of the variants with an alternate allele fre-
quency ≤5%, while the other methods only detect 30% of
the variants. MutaScope offers an analysis strategy speci-
fically dedicated to the identification of low prevalence
somatic mutations in high-throughput direct sequencing
of PCR amplicons. As a result MutaScope increases the
overall technical performance of such approaches that
are currently being implemented in clinical diagnostics
laboratories.
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